MGCD-265
CAY-20097-25 25 mg
Data Sheet: 
SDS:
SDS:
CAS
875337-44-3
Formulation
A crystalline solid
Purity
≥98%
MW
517,6
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A c-Met and VEGFR2 inhibitor (IC50s = 0.029 and 0.01 µM, respectively); selective for c-Met and VEGFR2 over Chk1, EGFR, GSK3β, IGF-1R, IKKβ, JAK2, and JNK1 at 0.1 µM; inhibits VEGFR1, VEGFR3, Ron, Tie2, FLT3, c-Kit, Abl, and TrkA by 80-100% at 0.1 µM; binds to Smo in HEK293T cell membranes expressing the human receptor (Ki = 0.0417 µM for the wild-type receptor); inhibits Gli1-mediated transcription in a reporter assay in gefitinib-resistant HCC827 cells; inhibits HGF-induced migration of A549 cells and VEGF-induced proliferation of HUVECs (IC50s = 2 and 0.025 µM, respectively); reduces tumor growth in several mouse xenograft models, including prostate, colorectal, and gastric cancer models at 20 mg/kg
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
